Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Oct 8, 2014
Metabolic therapies that induce a state of mild ketosis from caloric restriction or the ketogenic diet offer neuroprotection against a wide range of pathologies, and continues to be an emerging strategy for the metabolic management of cancer. Severe dietary restriction of calories or carbohydrates is typically needed to produce a level of ketosis that achieves therapeutic benefits. Interestingly, the strategy to use exogenous ketones as an alternative fuel has not been exploited therapeutically. When administered orally in controlled dosages, ketone esters and other ketogenic agents can lower glucose and elevate plasma ketone levels comparable to levels achieved by the most rigorous ketogenic diets. Metabolic therapies in the form of ketone supplementation offer a safe, convenient, and versatile new treatment approach for a variety of diseases, including seizure disorders, neurodegenerative diseases and cancer.
Dominic D’Agostino is an Assistant Professor at the University of South Florida’s Morsani College of Medicine. Dr. D’Agostino teaches in the Department of Molecular Pharmacology and Physiology with an emphasis on such topics as Biochemistry, Neuropharmacology and Nutrition. His research is focused on developing and testing nutritional strategies for promoting healthy weight loss and enhancing cognitive and physical performance. In addition, his research aims to develop and test specific metabolic therapies and supplements for neurological diseases and cancer. Dr. D’Agostino’s research is supported by the Office of Naval Research (ONR), Department of Defense (DoD) and private foundations.